A modern view of excipient effects on bioequivalence: Case study of sorbitol

Pharmaceutical Research

Volumn 24, Issue 1, 2007, Pages 73-80

  Chen, M L ^a   Straughn, A B ^b   Sadrieh, N ^a   Meyer, M ^c   Faustino, P J ^a   Ciavarella, A B ^a   Meibohm, B ^b   Yates, C R ^b   Hussain, A S ^a,d  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c Life Sciences Building 64 ^*  (United States)

^d Sandoz Pharma Ltd   (Switzerland)

Author keywords

Bioavailability; Bioequivalence; Excipient; Permeability; Sorbitol

Indexed keywords

DEXTRORPHAN; EXCIPIENT; METOPROLOL TARTRATE; RANITIDINE; SORBITOL; SUCROSE;

AREA UNDER THE CURVE; ARTICLE; BIOAVAILABILITY; BIOEQUIVALENCE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG EFFECT; DRUG EXPOSURE; DRUG FORMULATION; DRUG PENETRATION; FEMALE; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE;

ADRENERGIC BETA-ANTAGONISTS; ADULT; ANTI-ULCER AGENTS; AREA UNDER CURVE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; DATA INTERPRETATION, STATISTICAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EXCIPIENTS; FEMALE; HUMANS; INTESTINAL ABSORPTION; MALE; METOPROLOL; PHARMACEUTIC AIDS; PHARMACEUTICAL SOLUTIONS; RANITIDINE; SORBITOL; SUCROSE; THERAPEUTIC EQUIVALENCY;

EID: 33845404173     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-006-9120-4     Document Type: Article

References (66)

1. G. L. Amidon, H. Lennernas, V. P. Shah, and J. R. Crison. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 12:413-420 (1995).
2. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville Maryland 20857, August 2000.
3. D. M. Woodcock, S. Jefferson, M. E. Linsenmeyer, P. J. Crowther, G. M. Chojnowski, B. Williams, and I. Bertoncello. Reversal of the multi-drug resistance phenotype with Cremophor EL, a common vehicle for water-insoluble vitamins and drugs. Cancer Res. 50:4199-4203 (1990).
4. A. R. Fassihi, R. Dowse, and S. S. D. Robertson. Influence of sorbitol solution on the bioavailability of theophylline. Int. J. Pharm. 72:175-178 (1991).
5. K. M. Koch, A. F. Parr, J. J. Tomlinson, E. P. Sandefer, G. A. Digenis, K. H. Donn, and J. R. Powell. Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time. Pharm. Res. 10:1027-1030 (1993).
6. D. A. Adkin, S. S. Davis, R. A. Sparrow, P. D. Huckle, A. J. Philips, and I. R. Wilding. The effects of pharmaceutical excipients on small intestinal transit. Br. J. Clin. Pharmacol. 39:381-387 (1995).
7. P. P. Constantinides. Lipid microemulsions for improving drug dissolution and oral absorption: physical and biopharmaceutical aspects. Pharm. Res. 12:1561-1572 (1995).
8. D. A. Adkin, S. S. Davis, R. A. Sparrow, P. D. Huckle, and I. R. Wilding. The effect of mannitol on the oral bioavailability of cimetidine. J. Pharm. Sci. 84:1405-1409 (1995).
9. R. A. Rajewski and V. J. Stella. Pharmaceutical applications of cyclodextrins. 2. In vivo drug delivery. J. Pharm. Sci. 85: 1142-1169 (1996).
10. L. Yu, A. Bridgers, J. Polli, A. Vickers, S. Long, A. Roy, R. Winnike, and M. Coffin. Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability. Pharm. Res. 16:1812-1817 (1999).
11. B. J. Aungst. Intestinal permeation enhancers. J. Pharm. Sci. 89:429-442 (2000).
12. A. Bernkop-Schnurch. Chitosan and its derivatives: potential excipients for peroral peptide delivery systems. Int. J. Pharm. 194:1-13 (2000).
13. A. Bernkop-Schnurch and C. E. Kast. Chemically modified chitosans as enzyme inhibitors. Adv. Drug Deliv. Rev. 52: 127-137 (2001).
14. A. W. Basit, F. Podczeck, J. M. Newton, W. A. Waddington, P. J. Ell, and L. F. Lacey. Influence of polyethylene glycol 400 on the gastrointestinal absorption of ranitidine. Pharm. Res. 19:1368-1374 (2002).
15. M. Martin-Facklam, J. Burhenne, R. Ding, R. Fricker, G. Mikus, I. Walter-Sack, et al. Dose-dependent increase of saquinavir bioavailability by the pharmaceutic aid Cremorphor EL. Br. J. Clin. Pharmacol. 53:576-581 (2002).
16. Y. Tayrouz, R. Ding, J. Burhenne, K. D. Riedel, J. Weiss, T. Hoppe-Tichy, W. E. Haefeli, and G. Mikus. Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40. Clin. Pharmacol. Ther. 73:397-405 (2003).
17. C. Wandel, R. Kim, and M. Stein. "Inactive" excipients such as Cremophor can affect in vivo drug disposition. Clin. Pharmacol. Ther. 73:394-396 (2003).
18. M.-L. Chen and L. J. Lesko. Individual bioequivalence revisited. Clin. Pharmacokinet. 40:701-706 (2001).
19. D. Farthing, K. L. R. Brouwer, I. Fakhry, and D. Sica. Solid-phase extraction and determination of ranitidine in human plasma by a high-performance liquid chromatographic method utilizing midbore chromatography. J. Chromatogr. B. 688:350-353 (1997).
20. B. Mistry, J. Leslie, and N. E. Eddington. A sensitive assay of metoprolol and its metabolite α-hydroxy metoprolol in human plasma and determination of dextromethorphan and its metabolite dextrorphan in urine with high performance liquid chromatography and fluorometric detection. J. Pharm. Biomed. Anal. 16:1041-1049 (1998).
21. D. J. Schuirmann. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J. Pharmacokinet. Biopharm. 15:657-680 (1987).
22. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Statistical Approaches to Establishing Bioequivalence, Office of Training and Communications, Division of Communications Management, Drug Information Branch, HFD-210, Rockville Maryland 20857, January 2001.
23. M.-L. Chen, R. Patnaik, W. W. Hauck, D. J. Schuirmann, T. Hyslop, and R. L. Williams. An individual bioequivalence criterion: regulatory considerations. Stat. Med. 19:2821-2842 (2000).
24. W. W. Hauck, T. Hyslop, M.-L. Chen, R. N. Patnaik, D. J. Schuirmann, R. L. Williams, and FDA Population/Individual Bioequivalence Working Group. Subject-by-formulation interaction in bioequivalence: conceptual and statistical issues. Pharm. Res. 17:375-380 (2000).
25. A. N. Wick, M. C. Almen, and L. Joseph. Metabolism of sorbitol. J. Am. Pharm. Assoc. 40:542-544 (1951).
26. J. D. Cryboski. Diarrhea from dietetic candies. N. Engl. J. Med. 275:718 (1966).
27. J. S. Hyams. Chronic abdominal pain caused by sorbitol malabsorption. J. Pediatr. 100:772-773 (1982).
28. R. E. Hill and K. R. Kamath. "Pink" diarrhea. Med. J. Aust. 1:387-389 (1982).
29. N. K. Jain, D. B. Rosenberg, M. J. Ulahannan, M. J. Glasser, and C. S. Pitchumoni. Sorbitol intolerance in adults. Am. J. Gastroenterol. 80:678-681 (1985).
30. J. S. Hyams. Sorbitol intolerance: an unappreciated cause of functional gastrointestinal complaints. Gastroenterol. 84:30-33 (1983).
31. D. B. Rosenberg, N. K. Jain, M. J. Ulahannan, et al. Sorbitol intolerance in adults and its relationship to lactose intolerance. Gastroenterol. 86:1356 (1984).
32. N. K. Jain, V. P. Patel, and C. S. Pitchumoni. Sorbitol intolerance in adults: prevalence and pathogenesis on two continents. J. Clin. Gastroenterol. 9:317-319 (1987).
33. M. S. Badiga, N. K. Jain, C. Casanova, and C. S. Pitchumoni. Diarrhea in diabetics: the role of sorbitol. J. Am. Coll. Nutr. 9:578-582 (1990).
34. D. Mishkin, L. Sablauskas, M. Yalovsky, and S. Mishkin. Fructose and sorbitol malabsorption in ambulatory patients with functional dyspepsia: comparison with lactose maldigestion/malabsorption. Dig. Dis. Sci. 42:2591-2598 (1997).
35. M. M. Smith, M. Davis, F. I. Chasalow, and F. Lifshitz. Carbohydrate absorption from fruit juice in young children. Pediatrics 95:340-344 (1995).
36. T. Nobigrot, F. I. Chasalow, and F. Lifshitz. Carbohydrate absorption from one serving of fruit juice in young children: age and carbohydrate composition effects. J. Am. Coll. Nutr. 16:152-158 (1997).
37. M. Marvola, A. Reinikainen, M. L. Heliovaara, and A. Huikari. The effects of some sweetening agents and osmotic pressure on the intestinal absorption of sulfafurazole in the rat. J. Pharm. Pharmacol. 31:615-618 (1979).
38. M. F. Williams, G. E. Dukes, W. Heizer, Y.-H. Han, D. J. Hermann, T. Lampkin, and L. J. Hak. Influence of gastrointestinal site of drug delivery on the absorption characteristics of ranitidine. Pharm. Res. 9:1190-1194 (1992).
39. T. Grammatte, E. El. Desoky, and U. Klotz. Site-dependent small intestinal absorption of ranitidine. Eur. J. Clin. Pharmacol. 46:253-259 (1994).
40. D. J. Kazierad, K. D. Schlanz, and M. B. Bottorff. Beta blockers. In W. E. Evans, J. J. Schentag, and W. J. Jusko (ed.), Applied Pharmacokinetics - Principles of Therapeutic Drug Monitoring, 3rd ed. Applied Therapeutics, Vancouver, WA, 1995, pp. 24-31.
41. D. L. Bourdet, J. B. Pritchard, and D. R. Thakker. Differential substrate and inhibitory activities of ranitidine and famotidine toward human organic cation transporter 1 (hOCT1; SLC22A1), hOCT2 (SLC22A2), and hOCT3 (SLC22A3). J. Pharmacol. Exp. Ther. 315:1288-1297 (2005).
42. 2 receptor antagonists. Eur. J. Clin. Pharmacol. 29:91-92 (1990).
43. N. Takamatsu, L. S. Welage, Y. Hayashi, R. Yamamoto, J. L. Barnett, V. P. Shah, L. J. Lesko, C. Ramachandran, and G. L. Amidon. Variability in cimetidine absorption and plasma double peaks following oral administration in the fasted state in humans: correlation with antral gastric motility. Eur. J. Pharm. Biopharm. 53:37-47 (2002).
44. A. Minocha, E. P. Krenzelok, and D. A. Spyker. Dosage recommendations for activated charcoal-sorbitol treatment. Clin. Toxicol. 23:579-587 (1985).
45. M. J. Ellenhorn and D. G. Barceloux. Medical Toxicology Diagnosis and Treatment of Human Poisoning, Elsevier, New York, 1988.
46. J. Glauser. Tricyclic antidepressant poisoning. Clevel. Clin. J. Med. 67:704-719 (2000).
47. American Academy of Clinical Toxicology and European Association of Poisons Centres and Clinical Toxicologists Position paper: cathartics. J. Toxicol. Clin. Toxicol. 42:243-253 (2004).
48. E. P. Krenzelok, R. Keller, and R. D. Stewart. Gastrointestinal transit times of cathartics combined with charcoal. Ann. Emerg. Med. 14:1152-1155 (1985).
49. M. Mayersohn, D. Perrier, and A. L. Picchioni. Evaluation of a charcoal-sorbitol mixture as an antidote for oral aspirin overdose. Clin. Toxicol. 11:561-567 (1977).
50. A. H. Al-Shareef, D. C. Buss, E. M. Allen, and P. A. Routledge. The effects of charcoal and sorbitol (alone and in combination) on plasma theophylline concentration after a sustained-release formulation. Human Exp. Toxicol. 9:179-182 (1990).
51. N. A. Minton and J. A. Henry. Prevention of drug absorption in simulated theophylline overdose. Clin. Toxicol. 33:43-49 (1995).
52. E. C. Scholtz, J. M. Jaffe, and J. L. Colazzi. Evaluation of five activated charcoal formulations for inhibition of aspirin absorption and palatability in man. Am. J. Hosp. Pharm. 35:1355-1359 (1978).
53. R. M. McNamara, C. K. Aaron, M. Gemborys, and S. Davidheiser. Sorbitol catharsis does not enhance efficacy of charcoal in a simulated acetaminophen overdose. Ann. Emerg. Med. 17:243-246 (1988).
54. C.-Y. Wu and L. Z. Benet. Predicting drug disposition via application of BCS: transport/absorption/elimination interplay and development of a biopharmaceutics disposition classification system. Pharm. Res. 22:11-23 (2005).
55. M. Lindenberg, S. Kopp, and J. B. Dressman. Classification of orally administered drugs on the World Health Organization Model list of Essential Medicines according to the biopharmaceutics classification system. Eur. J. Pharm. Biopharm. 58:265-278 (2004).
56. Goodman and Gilman's The Pharmacological Basis of Therapeutics. In J. G. Hardman and L. E. Limbird (eds.-in-chief), P. B. Molinoff and R. W. Ruddon (eds.), A. G. Gilman (consulting ed.), 9th ed. McGraw-Hill, New York, 1995, p. 1712.
57. R. E. Keller, R. A. Schwab, and E. P. Krenzelok. Contribution of sorbitol combined with activated charcoal in prevention of salicylate absorption. Ann. Emerg. Med. 19:654-656 (1990).
58. Digestion and absorption in the gastrointestinal tract. Chapter 65. In A. C. Guyton and J. E. Hall (eds.), Textbook of Medicinal Physiology, 9th ed, W.B. Saunders, Philadelphia, 1996, p. 834.
59. D. Kruger, R. Grossklaus, M. Herold, S. Lorenz, and L. Klingebiel. Gastrointestinal transit and digestibility of maltitol, sucrose and sorbitol in rats: a multicompartmental model and recovery study. Experientia 48:733-740 (1992).
60. H. A. Krebs. Some general considerations concerning the use of carbohydrates in parenteral nutrition. In I. D. A. Johnston (ed.), Advances in Parenteral Nutrition, MTP, Lancaster, 1978, pp. 23-28.
61. E. M. Hill, C. M. Flaitz, and G. R. Frost. Sweetener content of common pediatric oral liquid medications. Am. J. Hosp. Pharm. 45:135-142 (1988).
62. D. M. Lutomski, M. L. Gora, S. M. Wright, and J. E. Martin. Sorbitol content of selected oral liquids. Ann. Pharmacother. 27:269-274 (1993).
63. A. Kumar, R. D. Rawlings, and D. C. Beaman. The mystery ingredients: sweeteners, flavorings, dyes, and preservatives in analgesic/antipyretic, antihistamine/decongestant, cough and cold, antidiarrheal, and liquid theophylline preparations. Pediatrics 91:927-933 (1993).
64. R. E. Wrolstad and R. S. Shallenberger. Free sugars and sorbitol in fruits - A compilation from the literature. J. Assoc. Off. Anal. Chem. 64:91-103 (1981).
65. A. A. Moukarzel and M. T. Sabri. Gastric physiology and functions: effects of fruit juices. J. Am. Coll. Nutr. 15:18S-25S (1996).
66. R. A. Breitenbach. 'Halloween diarrhea' - An unexpected trick of sorbitol-containing candy. Postgrad. Med. 92:63-66 (1992).